S-Protein (Vitronektin) : Die Rolle des multifunktionellen Adhäsivproteins im Gerinnungs- und Komplementsystem an der Interphase Blut-Gefäßwand

• Literatur

• 1 Akama T, Yamada K.M, Seno N, Matsu-moto I, Kono I, Kashiwagi H, Funaki T, Hayashi M. Immunological characterization of human vitronectin and its binding to glycosaminoglycans. J Biochem 1986; 100: 1343-51.
• 2 Baker J.B, Gronke R.L. Protease nexins and cellular regulation. Sem Thromb Hemostas 1986; 12: 216-20.
• 3 Baker P.J, Lint T.F, McLeod B, Behrends C.L, Gewürz H. Studies on the inhibition of C56-induced lysis (reactive lysis). VI. Modulation of C56-induced lysis by poly-anions and polycations. J Immunol 1975; 114: 554-8.
• 4 Bar-Shavit R, Kahn A.J, Mann K.G, Wilner G.D. Identification of a thrombin sequence with growth factor activity on macrophages. Proc Natl Acad Sci USA 1986; 83: 976-80.
• 5 Barnes D.W, Reing J.E, Amos B. Hepa-rin-binding properties of human serum spreading factor. J Biol Chem 1985; 260: 9117-22.
• 6 Barnes D.W, Silnutzer J. Isolation of human serum spreading factor. J Biol Chem 1983; 258: 12548-52.
• 7 Barnes D.W, Silnutzer J, See C, Shaffer M. Characterization of human serum spreading factor with monoclonal antibody. Proc Natl Acad Sci USA 1983; 80: 1362-6.
• 8 Barnes D, Wolfe R, Serrero G, McClure D, Sato G. Effects of a serum spreading factor on growth and morphology of cells in serum-free medium. J Supramol Struct 1980; 14: 47-63.
• 9 Basara M.L, McCarthy J.B, Barnes D.W, Furcht L.T. Stimulation of haptotaxis and migration of tumor cells by serum spreading factor. Cancer Res 1985; 45: 2487-94.
• 10 Bauer P.I, Mandl J, Machovich R, Antoni F, Garzo T, Horvath I. Specific binding of thrombin-antithrombin III complex to he-patocytes. Thromb Res 1982; 28: 595-606.
• 11 Bertina R.M, van der Linden I.K, Engesser L, Muller H.P, Brommer E.J.P. Hereditary heparin cofactor II deficiency and the risk of development of thrombosis. Thromb Haemostas 1987; 57: 196-200.
• 12 Bhakdi S, Bhakdi-Lehnen B, Tranum-Jensen J. Proteolytic transformation of SC5b-9 into an amphiphilic macromolecule resembling the C5b-9 membrane attack complex of complement. Immunology 1979; 37: 901-12.
• 13 Binder B. On the complex formation of antithrombin III with thrombin. Gelfiltra-tion studies on human plasma and serum. Thrombos Diathes Haemorrh 1973; 30: 280-3.
• 14 Cardarelli P.M, Pierschbacher M.D. Identification of fibronectin receptors on T lymphocytes. J Cell Biol 1987; 105: 499-506.
• 15 Charo I.F, Bekeart L.S, Phillips D.R. Platelet glycoprotein IIb-IIIa-like proteins mediate endothelial cell attachment to adhesive proteins and the extracellular matrix. J Biol Chem 1987; 262: 9935-8.
• 16 Charo I.F, Fitzgerald L.A, Steiner B, Rail S.C, Bekeart L.S, Phillips D.R. Platelet glycoproteins IIb and Ilia: Evidence for a family of immunologically and structurally related glycoproteins in mammalian cells. Proc Natl Acad Sci USA 1986; 83: 8351-5.
• 17 Chen L.B, Buchanan J.M. Mitogenic activity of blood components. I. Thrombin and prothrombin. Proc Natl Acad Sci USA 1975; 72: 131-5.
• 18 Chen W-T, Wang J, Hasegawa T, Yamada S.S, Yamada K.M. Regulation of fibronectin receptor distribution by transformation, exogenous fibronectin, and synthetic peptides. J Cell Biol 1986; 103: 1649-61.
• 19 Cheresh D.A. Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Wille-brand factor. Proc Natl Acad Sci USA 1987; 84: 6471-5.
• 20 Chhatwal G.S, Blobel H. Binding of host plasma proteins to streptococci and their possible role in streptococcal pathogenicity. IRCS Med Sci 1986; 14: 1-3.
• 21 Chhatwal G.S, Dutra I.S, Blobel H. Fibrinogen binding inhibits the fixation of the third component of human complement on surface of groups A, B, C, and G streptococci. Microbiol Immunol 1985; 29: 973-80.
• 22 Chhatwal G.S, Preissner K.T, Müller-Berghaus G, Blobel H. Specific binding of the human S protein (vitronectin) to streptococci, Staphylococcus aureus, and Escherichia coli. Infect Immun 1987; 55: 1878-83.
• 23 Chinielewska J, Carlsson T, Urden G, Wiman B. On the relationship between different molecular forms of the fast inhibitor of tissue plasminogen activator. Fibrinolysis 1987; 1: 67-73.
• 24 Dahlbäck B, Podack E.R. Characterization of human S-protein, an inhibitor of the membrane attack complex of complement. Demonstration of a free reactive thiol group. Biochemistry 1985; 24: 2368-74.
• 25 Dahlbäck K, Lofberg H, Dahlbäck B. Localization of vitronectin (S-protein of complement) in normal human skin. Acta Derm Venereol 1986; 66: 461-7.
• 26 DeClerck P.J, De Mol M, Alessi M.C, Baudner S, Paques E-P, Preissner K.T, Müller-Berghaus G, Collen D. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimene form of S-protein (vitronectin). J Biol Chem 1988; (im Druck).
• 27 Dejana E, Languino L.R, Colella S, Cor-bascio G.C, Plow E, Ginsberg M, Marchisio P.C. The localization of a platelet GpIIb-IIIa-related protein in endothelial cell adhesion structures. Blood 1988; 71: 566-72.
• 28 Dejana E, Languino L.R, Polentarutti N, Balconi G, Ryckewaert J.J, Larrieu M.J, Donati M.B, Mantovani A, Marguerie G. Interaction between fibrinogen and cultured endothelial cells. Induction of migration and specific binding. J Clin Invest 1985; 75: 11-8.
• 29 Dejana E, Marchisio P.C, Preissner K.T, Müller-Berghaus G. Interaction of fibrinogen with endothelial cells. In: Forbes C.D, Lowe G.D.O, Douglas J.T, Gaffney P.J, Lane D.A, Cederholm-Williams S, Hensenen A. (Eds) Fibrinogen, Fibrin and its Derivatives. Amsterdam: Elsevier; 1988. (im Druck).
• 30 Delvos U, Meusel P, Preissner K.T, Müller-Berghaus G. Formation of activated protein C and inactivation of cell-bound thrombin by antithrombin III at the surface of cultured vascular endothelial cells -a comparative study of two anticoagulant mechanisms. Thromb Haemostas 1987; 57: 87-91.
• 31 Fair D.S, Plow E.F. Specific association of thrombin-antithrombin complexes with a human hepatoma cell line. Thromb Res 1986; 41: 67-78.
• 32 Falk R.J, Podack E, Dalmasso A.P, Jennette J.C. Localization of S-protein and its relationship to the membrane attack complex of complement in renal tissue. Am J Pathol 1987; 127: 182-90.
• 33 Fitzgerald L.A, Charo I.F, Phillips D.R. Human and bovine endothelial cells synthesize membrane proteins similar to human platelet glycoproteins IIb and Ilia. J Biol Chem 1985; 260: 10893-6.
• 34 Fryklund L, Sievertsson H. Primary structure of somatomedin B. A growth hormone-dependent serum factor with protease inhibiting activity. FEB S Lett 1978; 87: 55-60.
• 35 Fuchs H.E, Shifman M.A, Pizzo S.V. In vivo catabolism of alpha_rproteinase inhi-bitor-trypsin, antithrombin IILthrombin and alpha₂-macroglobulm-methylamine. Biochim Biophys Acta 1982; 716: 151-7.
• 36 Fuquay J.I, Loo D.T, Barnes D.W. Binding of Staphylococcus aureus by human serum spreading factor in an in vitro assay. Infect Immun 1986; 52: 714-7.
• 37 Gardner J.M, Hynes R.O. Interaction of fibronectin with its receptor on platelets. Cell 1985; 42: 439-48.
• 38 Gebb C, Hayman E.G, Engvall E, Ruos-lahti E. Interaction of vitronectin with collagen. J Biol Chem 1986; 261: 16698-703.
• 39 Gehlsen K.R, Argraves W.S, Pierschbacher M.D, Ruoslahti E. Inhibition of in vitro tumor cell invasion by Arg-Gly-Asp-containing synthetic peptides. J Cell Biol 1988; 106: 925-30.
• 40 Ginsberg M.H, Loftus J.C, Plow E.F. Cytoadhesins, integrins, and platelets. Thromb Haemostas 1988; 59: 1-6.
• 41 Ginsberg M.H, Loftus J, Ryckwaert J-J, Pierschbacher M, Pytela R, Ruoslahti E, Plow E.F. Immunochemical and amino-terminal sequence comparison of two cytoadhesins indicates they contain similar or identical ß-subunits and distinct alpha-subunits. J Biol Chem 1987; 262: 5437-40.
• 42 Ginsberg M, Pierschbacher M.D, Ruoslahti E, Marguerie G, Plow E. Inhibition of fibronectin binding to platelets by proteolytic fragments and synthetic peptides which support fibroblast adhesion. J Biol Chem 1985; 260: 3931-6.
• 43 Hänsch G.M, Schönermark S, Rölcke D. Paroxysmal nocturnal hemoglobinuria type III. Lack of an erythrocyte membrane protein restricting the lysis by C5b-9. J Clin Invest 1987; 80: 7-12.
• 44 Hanson S.R, Pareti F.I, Ruggeri Z.M, Marzee U.M, Kunicki T.J, Montgomery R.R, Zimmerman T.S, Harker L.A. Effects of monoclonal antibodies against the platelet glycoprotein IIb/IIIa complex on thrombosis and hemostasis in the baboon. J Clin Invest 1988; 81: 149-58.
• 45 Hayashi M, Akama T, Kono I, Kashiwagi H. Activation of vitronectin (serum spreading factor) – Binding of heparin by denaturing agents. J Biochem 1985; 98: 1135-8.
• 46 Hayman E.G, Engvall E, A’Hearn E, Barnes D, Pierschbacher M, Ruoslahti E. Cell attachment of replicas of SDS Polyacrylamide gels reveals two adhesive plasma proteins. J Cell Biol 1982; 95: 20-3.
• 47 Hayman E.G, Pierschbacher M.D, Öhgren Y, Ruoslahti E. Serum spreading factor (vitronectin) is present at the cell surface and in tissues. Proc Natl Acad Sci USA 1983; 80: 4003-7.
• 48 Hayman E.G, Pierschbacher M.D, Suzuki S, Ruoslahti E. Vitronectin – a major cell attachment-promoting protein in fetal bovine serum. Exp Cell Res 1985; 160: 245-58.
• 49 Heimburger N, Haupt H, Kranz T, Baud-ner S. Physikalisch-chemische und immunologische Charakterisierung eines histi-dinreichen 3,8S-alpha₂-Glykoproteins (CM-Protein I). Hoppe-Seyler’s Z Physiol Chem 1972; 353: 1133-40.
• 50 Hildebrand A, Preissner K.T, Müller-Berghaus G, Teschemacher H. Characterization of S-protein (vitronectin) as a ß-endorphin binding protein: Unmasking of specific binding sites upon interaction with heparin or surface association of S-protein. (Eingereicht zur Publikation).
• 51 Hildebrand A, Schweigerer L, Teschemacher H. Characterization and identification of heparin-induced nonopioid-binding sites for ß-endorphin in human plasma. J Biol Chem 1988; 263: 2436-41.
• 52 Holmes R. Preparation from human serum of an alpha-one protein which induces the immediate growth of unadapted cells in vitro. J Cell Biol 1967; 32: 297-308.
• 53 Humphries M.J, Olden K, Yamada K.M. A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science 1986; 233: 467-70.
• 54 Humphries M.J, Yamada K.M, Olden K. Investigation of thé biological effects of anti-cell adhesive synthetic peptides that inhibit experimental metastasis of B16-F10 murine melanoma cells. J Clin Invest 1988; 81: 782-90.
• 55 Hynes R.O. Integrins: A family of cell surface receptors. Cell 1987; 48: 549-54.
• 56 Hynes R.O, Yamada K.M. Fibronectins: multifunctional modular glycoproteins. J Cell biol 1982; 95: 369-77.
• 57 Ill C.R, Ruoslahti E. Association of throm-bin-antithrombin III complex with vitronectin in serum. J Biol Chem 1985; 260: 15610-5.
• 58 Jaffe E.A, Hoyer L.W, Nachman R.L. Synthesis of von Willebrand factor by cultured human endothelial cells. Proc Natl Acad Sci USA 1974; 71: 1906-9.
• 59 Jaffe E.A, Mosher D.F. Synthesis of fibronectin by cultured human endothelial cells. J Exp Med 1978; 147: 1779-91.
• 60 Jenne D, Hugo F, Bhakdi S. Monoclonal antibodies to human plasma protein X alias complement S-protein. Biosci Rep 1985; 4: 343-52.
• 61 Jenne D, Hugo F, Bhakdi S. Interaction of complement S-protein with thrombin-anti-thrombin complexes: A role for the Sprotein in haemostasis. Thromb Res 1985; 38: 401-12.
• 62 Jenne D, Stanley K.K. Molecular cloning of S-protein, a link between complement, coagulation and cell-substrate adhesion. EMBO J 1985; 4: 3153-7.
• 63 Jenne D, Stanley K.K. Nucleotide sequence and organization of the human S-protein gene: repeating peptide motifs in the “pexin” family and a model for their evolution. Biochemistry 1987; 26: 6735-42.
• 64 Jordan R.E, Favreau L.V, Braswell E.H, Rosenberg R.D. Heparin with two binding sites for antithrombin or platelet factor 4. J Biol Chem 1982; 257: 400-6.
• 65 Kemkes-Matthes B, Preissner K.T, Langenscheidt F, Matthes K.J, Müller-Berghaus G. S-protein/vitronectin in chronic liver diseases: Correlations with serum Cholinesterase, coagulation factor X and complement component C3. Eur J Haematol 1987; 39: 161-5.
• 66 Kolb W.P, Müller-Eberhard H.J. The membrane attack mechanism of complement. Isolation and subunit composition of the C5b-9 complex. J Exp Med 1975; 141: 724-35.
• 67 Lane D.A, Flynn A.M, Pejler G, Lindahl U, Choay J, Preissner K. Structural requirements for the neutralization of heparin-like saccharides by complement S-protein/ vitronectin. J Biol Chem 1987; 262: 16343-9.
• 68 Lane D.A, Pejler G, Flynn A.M, Thompson E.A, Lindahl U. Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4. J Biol Chem 1986; 261: 3980-6.
• 69 Lawrence J.B, Gralnick H.R. Monoclonal antibodies to the glycoprotein Ilb/IIIa epitopes involved in adhesive protein binding: Effects on platelet spreading and ultrastructure on human arterial subendo-thelium. J Lab Clin Med 1987; 109: 495-503.
• 70 Leeksma O.C, Zandbergen-Spaangaren J, Giltay J.C, van Mourik J.A. Cultured human endothelial cells synthesize a plasma membrane protein complex immunologically related to the platelet glycoprotein IIb/IIIa complex. Blood 1986; 67: 1176-80.
• 71 Lijnen H.R, Hoylaerts M, Collen D. Heparin binding properties of human histi-dine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma. J Biol Chem 1983; 258: 3803-8.
• 72 Lindahl U, Thunberg L, Bäckström G, Riesenfeld J, Nordling K, Björk I. Extension and structural variability of the anti-thrombin-binding sequence in heparin. J Biol Chem 1984; 259: 12368-76.
• 73 Lint T.F, Behrends C.L, Baker P.J, Gewürz H. Activation of the complement attack mechanism in the fluid phase and its control by C567-INH: Lysis of normal erythrocytes initiated by zymosan, endotoxin, and immune complexes. J Immunol 1976; 117: 1440-6.
• 74 Low D.A, Baker J.B, Koonce W.C, Cunningham D.D. Released protease-ne-xin regulates cellular binding, internalization, and degradation of serine proteases. Proc Natl Acad Sci USA 1981; 78: 2340-4.
• 75 Marciniak E, Gora-Maslak G. High molecular weight forms of antithrombin III complexes in blood. Thromb Haemostas 1983; 49: 32-6.
• 76 Marcum J.A, Atha D.H, Fritze L.M.S, Nawroth P, Stern D, Rosenberg R.D. Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulfate proteoglycan. J Biol Chem 1986; 261: 7507-17.
• 77 Marcum J.A, Rosenberg R.D. Anticoagulantly active heparin-like molecules from vascular tissue. Biochemistry 1984; 23: 1730-7.
• 78 Marguerie G.A, Ardaillou N, Cherel G, Plow E.F. The binding of fibrinogen to its platelet receptor. J Biol Chem 1982; 257: 11872-5.
• 79 McGuire E.A, Peacock M.E, Inhorn R, Siegel N.R, Tollefsen D.M. Phosphorylation of vitronectin by a protein kinase in human plasma. J Biol Chem 1988; 263: 1942-5.
• 80 McLeod B, Baker P, Gewürz H. Studies on the inhibition of C56-initiated lysis (reactive lysis). III. Characterization of the inhibitory activity C567-INH and its mode of action. Immunology 1975; 28: 133-49.
• 81 Müller-Eberhard H.J. The membrane attack complex of complement. Ann Rev Immunol 1986; 4: 503-28.
• 82 Nemerow G.R, Yamamoto K-I, Lint T.F. Restriction of complement-mediated membrane damage by the eight component of complement: a dual role for C8 in the complement attack sequence. J Immunol 1979; 123: 1245-52.
• 83 Newman P.J, Kawai Y, Montgomery R.R, Kunicki T.J. Synthesis by cultured human umbilical vein endothelial cells of two proteins structurally and immunologically related to platelet membrane glycoproteins lib and Ilia. J Cell Biol 1986; 103: 81-6.
• 84 Nicholson-Weiler A, Bürge J, Fearon D.T, Weller P.F, Austen K.F. Isolation of a human erythrocyte membrane glycoprotein with decay accelerating activity for C3 convertases of the complement system. J Immunol 1982; 129: 184-9.
• 85 Nicholson-Weiler A, March J.P, Rosenfeld S.I, Austen K.F. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci USA 1983; 80: 5066-70.
• 86 Niculescu F, Rus H.G, Vlaicu R. Immuno-histochemical localization of C5b-9, S-protein, C3d and apolipoprotein B in human arterial tissues with atherosclerosis. Atherosclerosis 1987; 65: 1-11.
• 87 Pangburn M.K, Schreiber R.D, Trombold J.S, Müller-Eberhard H.J. Paroxysmal nocturnal hemoglobinuria: Deficiency in factor H-like functions of the abnormal erythrocytes. J Exp Med 1983; 157: 1971-80.
• 88 Parker C.J, Frame R.N, Elstad M.R. Vitronectin (S-protein) augments the functional activity of monocyte receptors for IgG and complement C3b. Blood 1988; 71: 86-93.
• 89 Pepper D.S, Banhegyi D, Cash J.D. The different forms of antithrombin III in serum. Thrombos Haemostas 1977; 38: 494-503.
• 90 Pidard D, Montgomery R.R, Bennett J.S, Kunicki T.J. Interaction of AP-2, a monoclonal antibody specific for the human platelet glycoprotein IIb-IIIa complex, with intact platelets. J Biol Chem 1983; 258: 12582-6.
• 91 Pierschbacher M.D, Ruoslahti E. Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion. J Biol Chem 1987; 262: 17294-8.
• 92 Pierschbacher M.D, Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 1984; 309: 30-3.
• 93 Pierschbacher M.D, Ruoslahti E. Variants of the cell recognition site of fibronectin that retain attachment-promoting activity. Proc Natl Acad Sci USA 1984; 81: 5985-8.
• 94 Plow E.F, Loftus J.C, Levin E.G, Fair D.S, Dixon D, Forsyth J, Ginsburg M.H. Immunologie relationship between platelet membrane glycoprotein GP Ilb/IIIa and cell surface molecules expressed by a variety of cells. Proc Natl Acad Sci USA 1986; 83: 6002-6.
• 95 Podack E.R, Curd J.G, Griffin J.H, Müller-Eberhard H.J. The thrombin protecting function of a complement inhibitor in human plasma. Thromb Haemostas 1979; 42: 170.
• 96 Podack E.R, Curd J.G, Griffin J.M, Müller-Eberhard H.J. Dual function of the S-protein in the complement and coagulation systems of human plasma. Clin Res 1978; 26: 507a.
• 97 Podack E.R, Dahlbäck B, Griffin J.H. Interaction of S-protein of complement with thrombin and antithrombin III during coagulation. Protection of thrombin by S-protein from antithrombin III inactivation. J Biol Chem 1986; 261: 7387-92.
• 98 Podack E.R, Kolb W.P, Müller-Eberhard H.J. The SC5b-7 complex: Formation, isolation, properties, and subunit composition. J Immunol 1977; 119: 2024-9.
• 99 Podack E.R, Müller-Eberhard H.J. Binding of desoxycholate, phosphatidylcholine vesicles, lipoprotein and of the S-protein to complexes of terminal complement components. J Immunol 1978; 121: 1025-30.
• 100 Podack E.R, Müller-Eberhard H.J. Isolation of human S-protein, an inhibitor of the membrane attack complex of complement. J Biol Chem 1979; 254: 9908-14.
• 101 Podack E.R, Müller-Eberhard H.J. SC5b-9 complex of complement: Formation of the dimeric membrane attack complex by removal of S-protein. J Immunol 1980; 124: 1779-83.
• 102 Podack E.R, Preissner K.T, Müller-Eberhard H.J. Inhibition of C9 polymerization within the SC5b-9 complex of complement by S-protein. Acta Pathol Microbiol Immunol Scand 1984; 92 C) (Suppl 284 89-96.
• 103 Preissner K.T, Anders E, Grulich-Henn J, Müller-Berghaus G. Attachment of cultured human endothelial cells is promoted by specific association with S-protein (vitronectin) as well as with the ternary S-protein-thrombin-antithrombin III complex. Blood 1988; 71: 1581-9.
• 104 Preissner K.T, Anders E, Grulich-Henn J, Müller-Berghaus G. Adhesion of cultured human endothelial cells is promoted by specific association with S-protein (vitronectin) and S-protein-containing complexes. Demonstration of intracellular S-protein. Blood 1987; 70 (Suppl. 01) 407a.
• 105 Preissner K.T, Heimburger N, Anders E, Müller-Berghaus G. Physicochemical, immunochemical and functional comparison of human S-protein and vitronectin – Evidence for the identity of both plasma proteins. Biochem Biophys Res Commun 1986; 134: 951-6.
• 106 Preissner K.T, Holzhüter S, Müller-Berghaus G. Identification and partial characterization of platelet S-protein. Haemostasis 1988; 18 (Suppl. 02) 149-50.
• 107 Preissner K.T, Müller-Berghaus G. S-protein modulates the heparin-catalyzed inhibition of thrombin by antithrombin III. Evidence for a direct interaction of S-protein with heparin. Eur J Biochem 1986; 156: 645-50.
• 108 Preissner K.T, Müller-Berghaus G. Neutralisation and binding von heparin by S-protein/vitronectin in the inhibition of factor Xa by antithrombin III. Involvement of an inducible heparin binding domain of S-protein/vitronectin. J Biol Chem 1987; 262: 12247-53.
• 109 Preissner K.T, Podack E.R, Müller-Eberhard H.J. Localization of the S-protein within the inhibitor complexes SC5b-7, SC5b-8, and SC5b-9 of human complement. Immunobiol 1983; 164: 286.
• 110 Preissner K.T, Sie P. S-protein neutralizes the anticoagulant activity of glycosamino-glycans in the inhibition of thrombin by heparin cofactor II. Thromb Haemostas 1987; 58: 227.
• 111 Preissner K.T, Sie P. Modulation of heparin cofactor II function by S-protein (vitronectin) and formation of a ternary S-protein-thrombin-heparin cofactor II complex. Thromb Haemostas 1988 (im Druck).
• 112 Preissner K.T, Wassmuth R, Müller-Berghaus G. Physicochemical characterization of human S-protein and its function in the blood coagulation system. Biochem J 1985; 231: 349-55.
• 113 Preissner K.T, Zwicker L, Müller-Berghaus G. Formation, characterization and detection of a ternary complex between S-protein, thrombin and antithrombin III in serum. Biochem J 1987; 243: 105-11.
• 114 Pytela R, Pierschbacher M.D, Ginsberg M.H, Plow E.F, Ruoslahti E. Platelet membrane glycoprotein Ilb/IIIa: Members of a family of Arg-Gly-Asp-specific adhesion receptors. Science 1986; 231: 1559-62.
• 115 Pytela R, Pierschbacher M.D, Ruoslahti E. Identification and isolation of a 140 kd cell surface glycoprotein with properties expected of a fibronectin receptor. Cell 1985; 40: 191-8.
• 116 Pytela R, Pierschbacher M.D, Ruoslahti E. A 125/115-kDa cell surface receptor specific for vitronectin interacts with the argini-ne-glycine-aspartic acid adhesion sequence derived from fibronectin. Proc Natl Acad Sci USA 1985; 82: 5766-70.
• 117 Rovelli G, Preissner K.T, Monard D. Interaction of S-protein (vitronectin) with glia-derived-nexin. (In Vorbereitung).
• 118 Ruggeri Z.M, Houghten R.A, Russell S.R, Zimmerman T.S. Inhibition of platelet function with synthetic peptides designed to be high-affinity antagonists of fibrinogen binding to platelets. Proc Natl Acad Sci USA 1986; 83: 5708-12.
• 119 Ruoslahti E. Fibronectin in cell adhesion and invasion. Cancer Metastasis Rev 1984; 3: 43-51.
• 120 Ruoslahti E, Pierschbacher M.D. Arg-Gly-Asp: A versatile cell recognition signal. Cell 1986; 44: 517-8.
• 121 Ruoslahti E, Pierschbacher M.D. New perspectives in cell adhesion: RGD and integrins. Science 1987; 238: 491-7.
• 122 Ruoslahti E, Suzuki S, Hayman E.G, Il C.R, Pierschbacher M.D. Purification and characterization of vitronectin. Methods Enzymol 1987; 144: 430-7.
• 123 Salama A, Preissner K.T, Göttsche B, Müller-Berghaus G, Mueller-Eckhardt C. Complement inhibitor S-protein is associated with membranes of red blood cells from patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 1988; 68: 41-5.
• 124 Santoro S.A, Lawing Jr W.J. Competition for related but nonidentical binding sites on the glycoprotein IIb-IIIa complex by peptides derived from platelet adhesive proteins. Cell 1987; 48: 867-73.
• 125 Schönermark S, Rauterberg E.W, Shin M.L, Loke S, Rölcke D, Hänsch G.M. Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor. J Immunol 1986; 136: 1772-6.
• 126 Shifman M.A, Pizzo S.V. The in vivo metabolism of antithrombin III and antithrombin III complexes. J Biol Chem 1982; 257: 3243-8.
• 127 Sie P, Dupony D, Pichón J, Boneu B. Constitutional heparin cofactor II deficiency associated with recurrent thrombosis. The Lancet 1985; I: 414-6.
• 128 Simpson W.A, Hasty D.L.L, Mason J.M, Beachy E.H. Fibronectin-mediated binding of group A streptococci to human polymorphonuclear leukocytes. Infect Immun 1982; 37: 805-10.
• 129 Sommer J, Gloor S.M, Rovelli G.F, Hofsteenge J, Nick H, Meier R, Monard D. cDNA sequence coding for a rat glia-derived nexin and its homology to members of the serpin superfamily. Biochemistry 1987; 26: 6407-10.
• 130 Springer T.A, Dustin M.L, Kishimoto T.K, Marlin S.D. The lymphocyte function-associated LFA-1, CD2, and LFA-3 molecules : Cell adhesion receptors of the immune system. Ann Rev Immunol 1987; 5: 223-52.
• 131 Stanley K.K. Homology with hemopexin suggests a possible scavenging function of S-protein/vitronectin. FEBS Lett 1986; 199: 249-53.
• 132 Stenn K.S. Epibolin: A protein of human plasma that supports epithelial cell movement. Proc Natl Acad Sci USA 1981; 78: 6907-11.
• 133 Suzuki S, Argraves W.S, Pytela R, Arai H, Krusius T, Pierschbacher M.D, Ruoslahti E. cDNA and amino acid sequences of the cell adhesion protein receptor recognizing vitronectin reveal a transmembrane domain and homologies with other adhesion protein receptors. Proc Natl Acad Sci USA 1986; 83: 8614-8.
• 134 Suzuki S, Oldberg A, Hayman E.G, Pierschbacher M.D, Ruoslahti E. Complete amino acid sequence of human vitronectin deduced from cDNA. Similarity of cell attachment sites in vitronectin and fibronectin. EMBO J 1985; 4: 2519-24.
• 135 Suzuki S, Pierschbacher M.D, Hayman E.G, Nguyen K, Öhgren Y, Ruoslahti E. Domain structure of vitronectin. J Biol Chem 1984; 259: 15307-14.
• 136 Thiagarajan P, Kelly K.L. Exposure of binding sites for vitronectin on platelets following stimulation. J Biol Chem 1988; 263: 3035-8.
• 137 Tomasini J.B.R, Mosher D.F. On the identity of vitronectin and S-protein: Immunological crossreactivity and functional studies. Blood 1986; 68: 737-42.
• 138 Tschopp J, Masson D, Schafer S, Peitsch M, Preissner K.T. The heparin binding domain of S-protein/vitronectin binds to complement components C7, C8, C9 and perforin from cytolytic T-cells and inhibits their lytic activities. Biochemistry 1988; 27: 4103-9.
• 139 Tschopp J, Mollnes T.E. Antigenic cross-reactivity of the subunit of complement component C8 with the cysteine-rich domain shared by complement component C9 and low density lipoprotein receptor. Proc Natl Acad Sci USA 1986; 83: 4223-7.
• 140 Tschopp T.B, Weiss H.J, Baumgartner H.R. Decreased adhesion of platelets to subendothelium in von Willebrand’s disease. J Lab Clin Med 1974; 83: 296-300.
• 141 Valentin-Weigand P, Grulich-Henn J, Chhatwal G.S, Müller-Berghaus G, Blobel H, Preissner K.T. Complement S-protein (vitronectin) mediates the adherence of streptococci to human endothelial cells. Infect Immun 1988 (im Druck).
• 142 Wagner D.D, Olmsted J.B, Marder V.J. Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells. J Cell Biol 1982; 95: 355-60.
• 143 Whitnack E, Beachy E.H. Antiopsonic activity of fibrinogen bound to protein on the surface of group A streptococci. J Clin Invest 1982; 69: 1042-5.
• 144 Wiman B, Carlsson T, Chmielewska J. Evidence for a plasminogen activator inhibitor binding protein in plasma. Thromb Haemostas 1987; 58: 15.
• 145 Yamada K.M, Kennedy D.W. Peptide inhibitors of fibronectin, laminin, and other adhesion molecules: Unique and shared features. J Cell Physiol 1987; 130: 21-8.
• 146 Zalman L.S, Wood L.M, Müller-Eberhard H.J. Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologeous complement transmembrane channels. Proc Natl Acad Sci USA 1986; 83: 6975-9.